top of page


Innovation made easy
With MedMira's patented RVF Technology, there are a myriad of possibilities: As an example, our latest custom made product for one of our...

MedMira
19. Apr. 20241 Min. Lesezeit


MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent...

MedMira
13. März 20244 Min. Lesezeit
Corporate Update on Clinical Evaluation of MedMira’s Products
Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review...

MedMira
1. Feb. 20243 Min. Lesezeit


U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test
Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) MedMira Inc. proudly announces today the successful...

MedMira
13. Dez. 20233 Min. Lesezeit
FY 2023 Update
Corporate Update Throughout the reporting period, the Company achieved significant milestones in its pursuit of FDA and Health Canada...

MedMira
28. Nov. 20232 Min. Lesezeit
Update on MedMira’s Regulatory Path in Canada and the USA
Halifax, Nova Scotia, 27 September, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve...

MedMira
27. Sept. 20233 Min. Lesezeit
bottom of page
